Vanda Pharmaceuticals (NASDAQ:VNDA) Upgraded to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Vanda Pharmaceuticals (NASDAQ:VNDA) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. B. Riley Financial boosted their price target on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, December 31st. HC Wainwright lifted their target price on Vanda Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Finally, Jefferies Financial Group lifted their price target on shares of Vanda Pharmaceuticals from $5.00 to $7.50 and gave the company a “hold” rating in a report on Wednesday, December 31st. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.63.

Vanda Pharmaceuticals Stock Performance

Shares of Vanda Pharmaceuticals stock opened at $6.12 on Wednesday. The company has a current ratio of 3.12, a quick ratio of 3.10 and a debt-to-equity ratio of 0.01. The company has a market cap of $361.69 million, a PE ratio of -1.64 and a beta of 0.62. The company has a 50 day moving average of $7.34 and a 200-day moving average of $5.67. Vanda Pharmaceuticals has a 1-year low of $3.81 and a 1-year high of $9.60.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative net margin of 102.02% and a negative return on equity of 21.88%. The firm had revenue of $57.22 million during the quarter, compared to the consensus estimate of $59.28 million. As a group, equities research analysts forecast that Vanda Pharmaceuticals will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Torren Management LLC bought a new position in Vanda Pharmaceuticals in the 4th quarter valued at approximately $25,000. Russell Investments Group Ltd. increased its position in Vanda Pharmaceuticals by 456.6% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares during the period. CWM LLC raised its stake in shares of Vanda Pharmaceuticals by 424.6% during the second quarter. CWM LLC now owns 9,359 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 7,575 shares during the last quarter. Quarry LP bought a new position in shares of Vanda Pharmaceuticals during the third quarter valued at $53,000. Finally, Cerity Partners LLC acquired a new position in shares of Vanda Pharmaceuticals during the second quarter worth $69,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

More Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: Fanapt momentum: Full‑year 2025 Fanapt net sales rose 24% to $117.3M, driven by higher prescriptions — supports durable product revenue growth. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: NEREUS approval and Bysanti PDUFA: NEREUS (tradipitant) approved for prevention of motion‑induced vomiting; Bysanti (milsaperidone) NDA under FDA review with PDUFA target Feb 21, 2026 — a potential upside catalyst if approved. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst coverage mixed but constructive: recent buy/overweight ratings and price targets remain above the current share price (median target ~$12.50), indicating upside in some broker forecasts. Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Earnings miss and widening net loss: Q4 revenue (~$56–57M) missed estimates and diluted EPS was -2.39, substantially below forecasts; the company reported a large net loss and gross loss for the quarter. Vanda Pharmaceuticals Inc (VNDA) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Below‑consensus FY2026 revenue guidance: company guided to $230M–$260M vs. consensus ~$273M — guidance shortfall weighs on near‑term expectations. (Guidance noted in company release and market reports.)
• Negative Sentiment: Cash burn and balance sheet pressure: operating cash outflow increased, cash and equivalents fell to roughly $70M, and liabilities rose — increases focus on runway and financing risk. Vanda Pharmaceuticals (VNDA) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Investor litigation announced: Pomerantz LLP is investigating claims on behalf of Vanda investors — adds legal risk and near‑term uncertainty. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. – VNDA

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.